2.10Open2.10Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover4929.56%IV5.23%PremiumJul 19, 2024Expiry Date1.94Intrinsic Value100Multiplier0DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type-0.7722Delta0.1997Gamma1.46Leverage Ratio-6.2286Theta0.0000Rho-1.13Eff Leverage0.0001Vega
Poseida Therapeutics Stock Discussion
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
No comment yet